A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis

NCT02969525 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

206

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriatic Arthritis

Interventions

OTHER: Placebo
DRUG: Bimekizumab

Sponsor

UCB Biopharma S.P.R.L.